TRCT
IMMX icon

Tower Research Capital (TRC)’s Immix Biopharma IMMX Stock Holding History

Tower Research Capital (TRC)’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.2K Buy
+2,929
New +$27.2K ﹤0.01% 3175
2026
Q1 		– Sell
-12,163
Closed -$63.6K – 5323
2025
Q4 		$63.6K Buy
+12,163
New +$50.1K ﹤0.01% 2250
2025
Q3 		– Sell
-131
Closed -$271 – 5403
2025
Q2 		$271 Sell
131
-340
-72% -$684 ﹤0.01% 5074
2025
Q1 		$791 Buy
471
+290
+160% +$547 ﹤0.01% 4830
2024
Q4 		$398 Sell
181
-2,929
-94% -$5.35K ﹤0.01% 5287
2024
Q3 		$4.63K Sell
3,110
-876
-22% -$1.76K ﹤0.01% 4467
2024
Q2 		$7.89K Sell
3,986
-1,710
-30% -$3.93K ﹤0.01% 4416
2024
Q1 		$17.5K Buy
5,696
+5,119
+887% +$19.8K ﹤0.01% 3119
2023
Q4 		$3.99K Buy
+577
New +$2.61K ﹤0.01% 5011
2023
Q3 		– Sell
-120
Closed -$323 – 6077
2023
Q2 		$323 Sell
120
-6,255
-98% -$13.1K ﹤0.01% 5689
2023
Q1 		$12K Buy
6,375
+4,019
+171% +$8.88K ﹤0.01% 4087
2022
Q4 		$5K Buy
2,356
+2,106
+842% +$2.81K ﹤0.01% 4872
2022
Q3 		$0 Buy
+250
New +$546 ﹤0.01% 6260

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC)'s IMMX Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in Immix Biopharma (IMMX) in Q2 2026: 2,929 shares worth $30.2K. The stake represents ﹤0.01% of the portfolio and ranks #3175 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in IMMX as recently as Q4 2025.

Tower Research Capital (TRC) first reported a position in IMMX in Q3 2022 and has held it in 13 quarters since. The position peaked at $63.6K in Q4 2025. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • Tower Research Capital (TRC) held 2,929 shares of Immix Biopharma worth $30.2K as of Q2 2026.
  • Immix Biopharma was a new Tower Research Capital (TRC) position in Q2 2026.
  • Immix Biopharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3175 holding.
  • Tower Research Capital (TRC) first reported a position in Immix Biopharma in Q3 2022 and has held it in 13 quarters since.
  • Tower Research Capital (TRC)'s Immix Biopharma position peaked at $63.6K in Q4 2025.
  • 109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.